AS1413 phase III AML data now expected Q1 2011

London, UK, and Cambridge, MA: 30 November 2010 - During its presentation today
at the Piper Jaffray conference, Antisoma plc (LSE: ASM; USOTC: ATSMY) will
announce that it now expects to report pivotal data for its cancer drug AS1413
(amonafide L-malate) in the first quarter of 2011. Previous guidance was that
the ACCEDE phase III trial, which evaluates AS1413 in patients with secondary
acute myeloid leukaemia (secondary AML), would report by the end of June 2011.
 
Glyn Edwards, CEO of Antisoma, said: "Gathering and processing of data in the
AS1413 trial is going well, so we now expect to announce results in the first
quarter of next year. This is the largest prospective study to date in patients
with secondary AML, and we look forward to sharing the findings with the
oncology community."
 
Today's presentation at the Piper Jaffray conference is available as an audio
webcast at www.antisoma.com. The presentation takes place in New York at 1.30 pm
EST/ 6.30 pm GMT today. To access the webcast live, please log on 15 minutes
early in order to register and download any necessary software.
 
 Enquiries:
 
 Glyn Edwards, CEO
 
 Daniel Elger, VP Marketing & Communications   +44 (0)7909 915 068
 
 Antisoma plc
 
Mark Court/Jessica Fontaine                   +44 (0)20 7466 5000
 
 Buchanan Communications
 
Except for the historical information presented, certain matters discussed in
this announcement are forward looking statements that are subject to a number of
risks and uncertainties that could cause actual results to differ materially
from results, performance or achievements expressed or implied by such
statements. These risks and uncertainties may be associated with product
discovery and development, including statements regarding the Company's clinical
development programmes, the expected timing of clinical trials and regulatory
filings. Such statements are based on management's current expectations, but
actual results may differ materially.
 
About AS1413 (amonafide L-malate)
AS1413 (amonafide L-malate) was added to Antisoma's pipeline through the
acquisition of Xanthus Pharmaceuticals, Inc. in June 2008. AS1413 is a novel DNA
intercalator that induces apoptotic signalling by blocking topoisomerase II
binding to DNA. This differs from the action of classical topoisomerase II
inhibitors, which induce apoptosis by causing extensive DNA damage. A further
distinctive feature of AS1413 is its ability to evade Pgp and related
transporters responsible for multi-drug resistance (MDR).
 
The ACCEDE phase III trial is evaluating AS1413 in patients with secondary AML.
These patients represent a substantial subgroup of AML patients whose disease is
associated with a history of myelodysplastic syndrome (MDS) or with prior
chemotherapy or radiotherapy treatment for other cancers. Patients with
secondary AML respond poorly to current AML therapies. Antisoma's trial compares
a novel treatment regimen of AS1413 plus cytarabine with a standard current
regimen of daunorubicin and cytarabine. Enrolment of over 420 patients was
completed in September 2010.
 
Background on Antisoma
Antisoma is a London Stock Exchange-listed biopharmaceutical company that
develops novel products for the treatment of cancer. The Company has operations
in the UK and the US. Please visitwww.antisoma.com for further information about
Antisoma.
 
[HUG#1466722]
 
This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
 
Source: Antisoma plc via Thomson Reuters ONE